Ultragenyx Pharmaceutical Inc (RARE)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Emil D. Kakkis
Employees:
1,310
60 LEVERONI COURT, NOVATO, CA 94949
415-483-8800

Ultragenyx Pharmaceutical Inc. focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the. treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia.

Data derived from most recent annual or quarterly report
Market Cap 2.761 Billion Shares Outstanding71.5 Million Avg 30-day Volume 757.896 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-3.5
Price to Revenue6.2282 Debt to Equity0.0 EBITDA-582.786 Million
Price to Book Value80.5587 Operating Margin-144.5099 Enterprise Value2.027 Billion
Current Ratio2.359 EPS Growth0.077 Quick Ratio2.053
1 Yr BETA 1.0786 52-week High/Low 54.98 / 31.52 Profit Margin-154.8694
Operating Cash Flow Growth-39.7069 Free Cash Flow to Firm (FCFF) TTM -459.656 Million Free Cash Flow to Equity (FCFE) TTM
Altman Z-Score-3.3405

Are you looking for these stocks instead?

View SEC Filings from RARE instead.

View recent insider trading info

Ultragenyx Pharmaceutical Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding RARE (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding RARE

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-10-23 by KAKKIS EMIL D
  • 4: filed on 2023-10-10 by HORN HOWARD
  • 3: filed on 2023-10-10 by HORN HOWARD
  • 4: filed on 2023-09-29 by HUIZENGA THEODORE ALAN
  • 4: filed on 2023-09-29 by CROMBEZ ERIC
  • 4: filed on 2023-09-11 by HUIZENGA THEODORE ALAN
  • 4: filed on 2023-09-06 by HARRIS ERIK
  • 4: filed on 2023-09-06 by HUIZENGA THEODORE ALAN
  • 4: filed on 2023-06-30 by SANDERS CORAZON (CORSEE) D.
  • 4: filed on 2023-06-21 by HARRIS ERIK

    • Events (8k)

  • 8-K: filed on 2023-11-02:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-10-23:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-10-16:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-09-08:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-08-03:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-07-12:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-07-06:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-06-13:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2023-06-05:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-17:
    Item 8.01: Other Events

    • Proposed Sales (Form 144)

  • 144: filed on 2023-10-23:
  • 144: filed on 2023-10-19:
  • 144: filed on 2023-05-18:
  • 144: filed on 2023-05-04:
  • 144: filed on 2023-06-08:
  • 144: filed on 2023-06-30:
  • 144: filed on 2023-09-05:
  • 144: filed on 2023-09-07:

    • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    87.7 Thousand total shares from 2 transactions

    Exercise Derivative Conversion (M)

    87.7 Thousand total shares from 2 transactions

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    KASSBERG THOMAS RICHARD CBO & EVP

    • Officer
    		 246,860 2023-10-23 2

    KAKKIS EMIL D PRESIDENT & CEO

    • Officer
    • Director
    		 3,510,757 2023-10-19 3

    HORN HOWARD CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2023-10-09 2

    HUIZENGA THEODORE ALAN SVP, CHIEF ACCOUNTING OFFICER

    • Officer
    		 23,614 2023-09-27 8

    CROMBEZ ERIC EVP AND CHIEF MEDICAL OFFICER

    • Officer
    		 30,512 2023-09-27 3

    HARRIS ERIK EVP & CHIEF COMMERCIAL OFFICER

    • Officer
    		 51,281 2023-09-05 3

    SANDERS CORAZON (CORSEE) D.

    • Director
    		 8,985 2023-06-30 2

    WELCH DANIEL G

    • Director
    		 21,605 2023-06-07 1

    DUNSIRE DEBORAH

    • Director
    		 19,730 2023-06-07 1

    NARACHI MICHAEL

    • Director
    		 21,605 2023-06-07 1

    FUST MATTHEW K

    • Director
    		 27,055 2023-06-07 1

    SULIMAN SHEHNAAZ

    • Director
    		 14,855 2023-06-07 1

    RAY AMRIT

    • Director
    		 12,280 2023-06-07 1

    PINION JOHN RICHARD SEE REMARKS

    • Officer
    		 74,744 2023-05-18 2

    PARSCHAUER KARAH HERDMAN EVP AND CHIEF LEGAL OFFICER

    • Officer
    		 51,982 2023-05-04 2

    BEDROSIAN CAMILLE L EVP AND CHIEF MEDICAL OFFICER

    • Officer
    		 46,720 2023-03-01 1

    HUANG DENNIS KARL SEE REMARKS

    • Officer
    		 64,715 2023-03-01 1

    DIER MARDI CFO & EXECUTIVE VICE PRESIDENT

    • Officer
    		 66,695 2022-10-14 0

    EKMAN LARS

    • Director
    		 23,990 2022-06-24 0

    ALISKI WILLIAM

    • Director
    		 147,655 2021-06-24 0

    SHARP SHALINI EVP, FINANCE

    • Officer
    		 97,812 2020-10-14 0

    SIEGALL CLAY B

    • Director
    		 2,550 2020-08-07 0

    HOGENHUIS WLADIMIR CHIEF OPERATING OFFICER

    • Officer
    		 18,703 2019-10-04 0

    DALLAS JAYSON DONALD ALEXANDER EVP & CHIEF COMMERCIAL OFFICER

    • Officer
    		 23,830 2018-06-01 0

    AGARWAL SUNIL CHIEF MEDICAL OFFICER

    • Officer
    		 9,136 2016-08-19 0

    FMR LLC

    • SEE REMARK 1.
    		 No longer subject to file 2014-08-01 0

    TPG GROUP HOLDINGS (SBS) ADVISORS, INC.

    BONDERMAN DAVID

    COULTER JAMES G

    • FORMER 10% OWNER (2)(3)(4)(5)FORMER 10% OWNER (2)(3)(4)(5)FORMER 10% OWNER (2)(3)(4)(5)
    		 No longer subject to file 2014-07-14 0

    NADAV ERAN

    • Director
    		 0 2014-07-10 0

    STEEN MARTEN

    • Director
    		 0 2014-01-30 0

    HAMPTON CATHY D VP , SEC. AND GENERAL COUNSEL

    • Officer
    		 0 2007-04-16 0

    MARTIN JOHN VICE PRESIDENT

    • Officer
    • PRESIDENT-CAPITAL GRILLE
    		 11,365 2007-03-14 0

    SAN MARTIN RONALD W

    • Director
    		 222,452 2007-03-09 0

    HICKEY PHILIP J JR CEO AND CHAIRMAN OF THE BOARD

    • Officer
    • Director
    		 159,434 2007-03-09 0

    LEE EUGENE I JR PRESIDENT AND COO-RARE

    • Officer
    • Director
    		 81,300 2007-03-08 0

    BENN W DOUGLAS CHIEF FINANCIAL OFFICER

    • Officer
    		 41,772 2007-03-05 0

    JOHNSON JOIA M EXEC. VP, GEN. COUNSEL, SEC.

    • Officer
    		 6,714 2007-02-16 0

    CHAPMAN DON L

    • Director
    		 17,571 2007-01-22 0

    NYHOF KRISTIN R VICE PRESIDENT

    • Officer
    • PRESIDENT-BUGABOO CREEK
    		 14,649 2006-05-18 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    KASSBERG THOMAS RICHARD - Officer CBO & EVP

    		2023-10-24 17:22:48 -0400 2023-10-23 M 39,878 $6.86 a 286,738 direct yes 5.1173 9.7776 9.7776 6 -0.0609 3

    KASSBERG THOMAS RICHARD - Officer CBO & EVP

    		2023-10-24 17:22:48 -0400 2023-10-23 S 39,878 $32.78 d 246,860 direct yes 5.1173 9.7776 9.7776 6 -0.0609 3

    KASSBERG THOMAS RICHARD - Officer CBO & EVP

    		2023-10-24 17:22:48 -0400 2023-10-23 M 39,878 d 0 direct yes

    KAKKIS EMIL D - Director - Officer PRESIDENT & CEO

    		2023-10-23 17:14:33 -0400 2023-10-19 M 47,853 $6.86 a 647,029 direct yes 2.0199 10.0062 10.0062 6 0.0 1

    KAKKIS EMIL D - Director - Officer PRESIDENT & CEO

    		2023-10-23 17:14:33 -0400 2023-10-19 S 47,853 $33.52 d 599,743 direct 2.0199 10.0062 10.0062 6 0.0 1

    KAKKIS EMIL D - Director - Officer PRESIDENT & CEO

    		2023-10-23 17:14:33 -0400 2023-10-19 M 47,853 d 0 direct

    HORN HOWARD - Officer CHIEF FINANCIAL OFFICER

    		2023-10-10 12:50:04 -0400 2023-10-09 A 80,366 a 80,336 direct -0.929 0.6284 6.1202 9.2077 29 -13.306 7

    HORN HOWARD - Officer CHIEF FINANCIAL OFFICER

    		2023-10-10 12:50:04 -0400 2023-10-09 A 140,469 a 140,469 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    ULTRAGENYX PHARMACEUTICAL IN RARE 2023-11-28 22:15:04 UTC 4.9119 0.4081 2500000
    ULTRAGENYX PHARMACEUTICAL IN RARE 2023-11-28 21:45:03 UTC 4.9119 0.4081 2500000
    ULTRAGENYX PHARMACEUTICAL IN RARE 2023-11-28 21:15:04 UTC 4.9119 0.4081 2500000
    ULTRAGENYX PHARMACEUTICAL IN RARE 2023-11-28 20:45:04 UTC 4.9119 0.4081 2500000
    ULTRAGENYX PHARMACEUTICAL IN RARE 2023-11-28 20:15:04 UTC 4.9119 0.4081 2500000
    ULTRAGENYX PHARMACEUTICAL IN RARE 2023-11-28 19:45:03 UTC 4.9119 0.4081 2500000
    ULTRAGENYX PHARMACEUTICAL IN RARE 2023-11-28 19:15:04 UTC 4.9119 0.4081 2500000
    ULTRAGENYX PHARMACEUTICAL IN RARE 2023-11-28 18:45:03 UTC 4.9119 0.4081 2500000
    ULTRAGENYX PHARMACEUTICAL IN RARE 2023-11-28 18:15:03 UTC 4.9119 0.4081 2500000
    ULTRAGENYX PHARMACEUTICAL IN RARE 2023-11-28 17:45:04 UTC 4.9119 0.4081 2500000
    ULTRAGENYX PHARMACEUTICAL IN RARE 2023-11-28 17:15:04 UTC 4.9119 0.4081 2500000
    ULTRAGENYX PHARMACEUTICAL IN RARE 2023-11-28 16:45:04 UTC 4.9119 0.4081 2500000
    ULTRAGENYX PHARMACEUTICAL IN RARE 2023-11-28 16:15:04 UTC 4.9119 0.4081 2500000
    ULTRAGENYX PHARMACEUTICAL IN RARE 2023-11-28 15:45:03 UTC 4.9119 0.4081 2500000
    ULTRAGENYX PHARMACEUTICAL IN RARE 2023-11-28 15:15:03 UTC 4.9119 0.4081 2500000
    ULTRAGENYX PHARMACEUTICAL IN RARE 2023-11-28 14:45:04 UTC 4.9119 0.4081 2500000
    ULTRAGENYX PHARMACEUTICAL IN RARE 2023-11-28 14:15:04 UTC 4.9119 0.4081 2500000
    ULTRAGENYX PHARMACEUTICAL IN RARE 2023-11-28 13:45:04 UTC 4.9119 0.4081 2500000
    ULTRAGENYX PHARMACEUTICAL IN RARE 2023-11-28 13:15:03 UTC 4.9119 0.4081 2500000
    ULTRAGENYX PHARMACEUTICAL IN RARE 2023-11-28 12:45:04 UTC 4.9119 0.4081 1800000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    American Century Quantitative Equity Funds, Inc.- AC Alternatives Disciplined Long Short Fund RARE -1795.0 shares, $-76664.45 2019-12-31 N-PORT
    AGF Investments Trust- AGFIQ U.S. Market Neutral Value Fund RARE -36.0 shares, $-2958.84 2020-09-30 N-PORT
    FundVantage Trust- Gotham Defensive Long Fund RARE -94.0 shares, $-4176.42 2020-03-31 N-PORT
    FundVantage Trust- Gotham Index Plus All-Cap Fund RARE -36.0 shares, $-1599.48 2020-03-31 N-PORT
    INVESTMENT MANAGERS SERIES TRUST- AAM HIMCO Global Enhanced Dividend Fund RARE -1228.0 shares, $-139820.08 2021-03-31 N-PORT
    FundVantage Trust- Gotham Hedged Plus Fund RARE -1268.0 shares, $-58746.44 2022-12-30 N-PORT
    AQR Funds- AQR Alternative Risk Premia Fund RARE -4798.0 shares, $-171048.7 2023-09-30 N-PORT
    AQR Funds- AQR Multi-Asset Fund RARE -5037.0 shares, $-179569.05 2023-09-30 N-PORT
    Federated Hermes Adviser Series- Federated Hermes MDT Market Neutral Fund RARE -8921.0 shares, $-318033.65 2023-09-30 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments